AstraZeneca vaccine study put on hold

feature image
AstraZeneca's Covid-19 vaccine phase 3 trial has been put on hold due to a suspected serious adverse reaction in a participant in the U.K., according to the Stat News. 

From a chartist point of view, the stock price remains in consolidation mode below the key resistance threshold at 8736p. A morning star pattern has formed but the signal still needs to be confirmed. The daily Relative Strength Index (RSI, 14) is reversing up but remains below 50% and remains capped by a declining trend line. The 20/50DMAs still play a resistance role. As long as 8736p is resistance, the risk of a break below the swing low at 7930p will remain high. Alternatively, a push above 8736p would reinstate a bullish bias with 9350p as first target.

Source: GAIN Capital, TradingView


Related tags: epidemic equities

Open an account in minutes

Experience award-winning platforms with fast and secure execution.

Live Trading Webinars

Our interactive webinars, led by our industry experts, come highly recommended and can help provide your trading with the edge it needs.
Economic Calendar